Status:
COMPLETED
Study of Lactobacillus in Adjuvant Treatment of RVVC
Lead Sponsor:
Peking University Shenzhen Hospital
Conditions:
Recurrent Vulvovaginal Candidiasis
Eligibility:
FEMALE
18-52 years
Phase:
PHASE4
Brief Summary
We are trying to determine if Clotrimazole vaginal tablets with oral Lactobacillus is better than Clotrimazole vaginal tablets in Preventing the Recurrence of vulvovaginalcandidiasis
Detailed Description
vulvovaginal candidiasis is common disease in women. Its refractory and high recurrence rate has always been a clinical problem. Some cases even recur several times a year, and those who recur more th...
Eligibility Criteria
Inclusion
- Women be at least 18 years of age
- Have symptoms of vulva irritation and or abnormal discharge
- Meet the clinical criteria for RVVC
- Willing to participate in research
Exclusion
- Taking / injecting antibiotics in the past two weeks;
- A woman who intends to be pregnant, pregnant or lactating;
- Long term use of contraceptives and immunosuppressants;
- Postmenopausal;
- There was no same fixed sexual partner (RSP) before and after treatment
- Patients with severe gastrointestinal diseases, including colorectal cancer, IBS, IBD, chronic or acute diarrhea, long-term constipation, etc., or receiving gastrointestinal surgery and abdominal surgery within one year, such as cholecystectomy;
- Patients with severe heart, liver and kidney dysfunction, mental diseases, infectious diseases, tumors, severe anemia, and severe autoimmune diseases (such as rheumatoid arthritis, lupus erythematosus, etc.)
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2023
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT04699240
Start Date
July 1 2020
End Date
December 30 2023
Last Update
June 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept Obstetrics and Gynecology
Shenzhen, Guangdong, China, 518036